| Drug General Information |
| Drug ID |
D05ICS
|
| Former ID |
DIB004891
|
| Drug Name |
ProSavin
|
| Synonyms |
Dopamine synthesis pathway gene therapy (Parkinson's disease), Oxford BioMedica
|
| Indication |
Parkinson's disease [ICD9: 332; ICD10:G20]
|
Phase 1/2 |
[1]
|
|---|
| Company |
Oxford BioMedica plc
|
| Target and Pathway |
| Target(s) |
GTP cyclohydrolase I |
Target Info |
Modulator |
[2]
|
|---|
| Aromatic-L-amino-acid decarboxylase |
Target Info |
Modulator |
[2]
|
| Tyrosine 3-monooxygenase |
Target Info |
Modulator |
[2]
|
|
BioCyc Pathway
|
Superpathway of tryptophan utilization
|
|
Tryptophan degradation via tryptamine
|
|
Serotonin and melatonin biosynthesis
|
|
Catecholamine biosynthesisPWY66-301:Catecholamine biosynthesis
|
|
KEGG Pathway
|
Histidine metabolism
|
|
Tyrosine metabolism
|
|
Phenylalanine metabolism
|
|
Tryptophan metabolism
|
|
Metabolic pathways
|
|
Serotonergic synapse
|
|
Dopaminergic synapse
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Alcoholismhsa00350:Tyrosine metabolism
|
|
Prolactin signaling pathway
|
|
Parkinson's disease
|
|
Alcoholism
|
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesis
|
|
5-Hydroxytryptamine biosynthesis
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
|
Parkinson disease
|
|
Nicotine pharmacodynamics pathway
|
|
Pathway Interaction Database
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
p38 signaling mediated by MAPKAP kinases
|
|
Alpha-synuclein signaling
|
|
PathWhiz Pathway
|
Pterine BiosynthesisPW000017:Catecholamine Biosynthesis
|
|
Tyrosine Metabolism
|
|
Tryptophan MetabolismPW000017:Catecholamine Biosynthesis
|
|
Reactome
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
|
WikiPathways
|
SIDS Susceptibility Pathways
|
|
Biogenic Amine Synthesis
|
|
Tryptophan metabolism
|
|
Dopaminergic Neurogenesis
|
|
Metabolism of amino acids and derivatives
|
|
Dopamine metabolism
|
|
Parkinsons Disease Pathway
|
|
Nicotine Activity on Dopaminergic NeuronsWP727:Monoamine Transport
|
|
Nicotine Activity on Dopaminergic Neurons
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01856439) Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease. U.S. National Institutes of Health. |
|---|
| REF 2 | Clinical pipeline report, company report or official report of Oxford BioMedica. |
|---|
